scholarly journals Turkish Version Study of “Parkinson’s Disease Quality of Life Questionnaire” (PDQL)

2015 ◽  
Vol 52 (2) ◽  
pp. 128-132 ◽  
Author(s):  
Elif Elcin Dereli ◽  
Ayse Yaliman ◽  
Tugba Kuru Colaka ◽  
Aycan Cakmak ◽  
Arzu Razak Ozdincler ◽  
...  
2017 ◽  
Vol 30 (5) ◽  
pp. 395 ◽  
Author(s):  
Joana Jesus-Ribeiro ◽  
Elsa Vieira ◽  
Pedro Ferreira ◽  
Cristina Januário ◽  
António Freire

Introduction: Parkinson’s disease has a significant impact in quality of life, which can be assessed with 39-item Parkinson’s Disease Questionnaire and Parkinson’s Disease Quality of Life Questionnaire. This study aimed to evaluate the reliability and validity of these scales in Portuguese patients.Material and Methods: Reliability was assessed through internal consistency (Cronbach’s alpha) and reproducibility (intraclass correlation coefficient). Regarding construct validity, we performed one-way analysis of variance across different groups according to modified Hoehn and Yahr scale. For criterion validity, we compared both scales with each other and with the Short Form 36-item Health Survey.Results: In a total of 100 patients with Parkinson’s disease, Cronbach’s alpha ranged for 39-item Parkinson’s Disease Questionnaire between 0.66 - 0.98, and for Parkinson’s Disease Quality of Life Questionnaire, between 0.78 - 0.98. Intraclass correlation coefficient for 39-item Parkinson’s Disease Questionnaire ranged between 0.49 - 0.96, and for Parkinson’s Disease Quality of Life Questionnaire, ranged between 0.65 - 0.96. Both scales showed, in general, capacity to discriminate differences among patients in the different stages of disease. The scales presented moderate to strong magnitude correlations with some Short Form 36-item Health Survey domains.Discussion: Cronbach’s alpha coefficients for most domains were satisfactory. Overall, it has been demonstrated good reproducibility, as well as construct and criterion validity.Conclusion: The Portuguese versions of both scales showed to be valid and reliable.


Author(s):  
Minako KAWAGUCHI ◽  
Yasushi MIYAGI ◽  
Junji KISHIMOTO ◽  
Kazuhiro SAMURA ◽  
Yutaka TOKUNAGA ◽  
...  

2015 ◽  
Vol 31 (4) ◽  
pp. 213-220 ◽  
Author(s):  
Teneille E. Gofton ◽  
Hrishikesh Kumar ◽  
Angela Roberts-South ◽  
Mark Speechley ◽  
Mandar S. Jog

Neurosurgery ◽  
2012 ◽  
Vol 71 (4) ◽  
pp. 815-825 ◽  
Author(s):  
Anna Rita Bentivoglio ◽  
Alfonso Fasano ◽  
Carla Piano ◽  
Francesco Soleti ◽  
Antonio Daniele ◽  
...  

Abstract BACKGROUND: The primary motor cortex, which is part of the corticobasal ganglia loops, may be an alternative option for the surgical treatment of Parkinson disease. OBJECTIVE: To report on the 1-year safety and efficacy of unilateral extradural motor cortex stimulation in Parkinson disease. METHODS: A quadripolar electrode strip was extradurally implanted over the motor cortex. Stimulation was continuously delivered through the electrode paddle contralateral to the most affected clinical side. Subjects were prospectively evaluated by the Unified Parkinson's Disease Rating Scale (UPDRS) and the Parkinson's Disease Quality of Life Questionnaire. In addition, an extensive cognitive and behavioral assessment and electroencephalogram recording were performed. RESULTS: Nine patients were included in this study. No surgical complications or adverse events occurred. Moreover, no cognitive or behavioral changes were observed. Under the off-medication condition, the UPDRS III at baseline was decreased by 14.1%, 23.3%, 19.9%, and 13.2%, at 1, 3, 6, and 12 months, respectively. The motor effects were bilateral, appeared after 3 to 4 weeks of stimulation, and outlasted the stimulation itself for 3 to 4 weeks in 1 case of stimulator accidental switching off. The UPDRS IV was decreased by 40.8%, 42.1%, and 35.5% at 1, 3, and 12 months, respectively. The scores on the Parkinson's Disease Quality of Life Questionnaire were increased at months 3, 6, and 12. CONCLUSION: Extradural motor cortex stimulation is a safe procedure. After 12 months, the patients demonstrated a moderate improvement of motor symptoms (particularly axial symptoms) and quality of life.


2021 ◽  
pp. 1-15
Author(s):  
Eduardo Tolosa ◽  
Georg Ebersbach ◽  
Joaquim J. Ferreira ◽  
Olivier Rascol ◽  
Angelo Antonini ◽  
...  

Background: A greater understanding of the everyday experiences of people with Parkinson’s disease (PD) and their carers may help improve clinical practice. Objective: The Parkinson’s Real-world Impact assesSMent (PRISM) study evaluated medication use, health-related quality of life (HRQoL) and the use of healthcare resources by people with PD and their carers. Methods: PRISM is an observational cross-sectional study, in which people with PD and their carers completed an online survey using structured questionnaires, including the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39), Non-Motor Symptoms Questionnaire (NMSQuest) and Zarit Burden Interview (ZBI). Results: Data were collected from 861 people with PD (mean age, 65.0 years; mean disease duration, 7.7 years) and 256 carers from six European countries. People with PD reported a large number of different co-morbidities, non-motor symptoms (mean NMSQuest score, 12.8), and impaired HRQoL (median PDQ-39 summary score, 29.1). Forty-five percent of people with PD reported at least one impulse control behaviour. Treatment patterns varied considerably between different European countries. Levodopa was taken in the last 12 months by 85.9% of participants, and as monotherapy by 21.8% . Carers, who were mostly female (64.8%) and the partner/spouse of the person with PD (82.1%), reported mild to moderate burden (mean ZBI total score, 26.6). Conclusions: The PRISM study sheds light on the lives of people with PD and those who care for them, re-emphasising the many challenges they face in everyday life. The study also provides insights into the current treatment of PD in Europe.


Sign in / Sign up

Export Citation Format

Share Document